Nakamura Mitsuhiro, Minemura Toshiyuki, Ishikura Satoshi, Nishio Teiji, Narita Yuichiro, Nishimura Yasumasa
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Japan.
Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Phys Med. 2016 Aug;32(8):987-91. doi: 10.1016/j.ejmp.2016.07.002. Epub 2016 Jul 9.
This study was undertaken to analyze the results of intensity-modulated radiotherapy (IMRT) dosimetry credentialing using a phantom in the Japanese Clinical Oncology Group clinical trials.
All measurements were performed on-site. The IMRT phantom consisted of a phantom shell and a module. Two types of structures, including a C-shaped planning target volume (PTV) around a column-shaped organ at risk (OAR), were included in the module. Each participating institution was asked to image, plan, and treat the phantom. A prescription dose of 2Gy should cover 95% of the PTV. The plan should limit the maximum doses to the PTV and OAR to less than 110% and 60%, respectively. The pass criteria were ±3% in terms of chamber dosimetry and a difference in profile position ⩽2mm in the high-dose gradient area of film dosimetry. The positional difference was defined as the largest distance between the measured and calculated positions at doses of 60% or 80%. These tolerances were based on the Japanese Society for Radiation Oncology IMRT guidelines.
Credentialing was performed on a total of 44 treatment machines in 32 institutions from 2009 to 2015. All differences between measured and planned doses at the measurement points of the PTV were within 3%. The means±standard deviations of the positional differences were 1.0±0.4mm and 0.9±0.3mm without and with the phantom shell, respectively.
The dose differences and positional differences met the desired criteria in all institutions.
本研究旨在分析在日本临床肿瘤学会的临床试验中使用体模进行调强放射治疗(IMRT)剂量验证的结果。
所有测量均在现场进行。IMRT体模由体模外壳和模块组成。模块中包含两种结构,包括围绕柱状危及器官(OAR)的C形计划靶区(PTV)。要求每个参与机构对体模进行成像、制定计划并进行治疗。处方剂量2Gy应覆盖PTV的95%。计划应将PTV和OAR的最大剂量分别限制在110%和60%以下。通过标准在电离室剂量测定方面为±3%,在胶片剂量测定的高剂量梯度区域轮廓位置差异≤2mm。位置差异定义为在60%或80%剂量下测量位置与计算位置之间的最大距离。这些公差基于日本放射肿瘤学会的IMRT指南。
2009年至2015年期间,对32个机构的44台治疗机器进行了资格认证。PTV测量点处测量剂量与计划剂量之间的所有差异均在3%以内。有无体模外壳时位置差异的平均值±标准差分别为1.0±0.4mm和0.9±0.3mm。
所有机构的剂量差异和位置差异均符合预期标准。